Rocket Lab SEC Filings

Frank Klein, Chief Operations Officer, executed multiple sales totaling 80,250 shares on March 2-4, 2026. Transactions included sell-to-cover for RSU vesting taxes and automatic sales under a 10b5-1 plan adopted September 2025. Neutral signal due to non-discretionary nature.

Chief Financial Officer Adam C. Spice sold 62,744 shares of RKLB common stock on 03/02/2026 via multiple sell-to-cover transactions to satisfy tax withholding on RSU vesting. The sales were pursuant to a Rule 10b5-1 plan. Neutral signal as routine non-discretionary tax-related sales.

Form 144 discloses Rocket Lab officer Arjun Kampani's intent to sell 23,711 shares of common stock, acquired via RSU vesting on 3/1/2026, valued at $1,662,852. The proposed sale on 3/4/2026 follows a sale of 28,761 shares on 3/1/2026 for $2M and is under a Rule 10b5-1 plan adopted 9/19/2025. This is routine insider activity relevant for tracking executive liquidity events.

Rocket Lab officer Frank Klein filed Form 144 on March 4, 2026, notifying of a proposed sale of 36,768 common shares acquired via RSU vesting on March 1, 2026, with an aggregate market value of $2,578,539.84. The sale is pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2025. Recent sales by Klein include 44,482 shares on March 1, 2026 ($3.1M) and 100,000 shares on January 2, 2026 ($7.3M), which are standard for vesting equity compensation.

This Form 144 filing by Peter Beck, Rocket Lab's CEO and Director, discloses the proposed sale of 18,857 common shares on March 2, 2026. The sales, totaling approximately $1.31 million, are to satisfy tax obligations from the vesting of 47,745 restricted stock units on March 1, 2026. It is a routine insider transaction with no sales reported in the prior three months.

Rocket Lab officer Arjun Kampani filed Form 144 on March 2, 2026, notifying of intent to sell 28,761 common shares acquired via restricted stock vesting. The sale, valued at approximately $2 million, covers tax obligations from the vesting of 52,472 RSUs on March 1, 2026. This is a routine compensation-related transaction with no prior sales by the filer in the past three months.

Rocket Lab officer Frank Klein filed Form 144 on March 2, 2026, notifying of intent to sell 44,482 common shares acquired from restricted stock unit vesting. The sale, executed via Morgan Stanley, includes shares needed to cover tax obligations and follows a prior sale of 100,000 shares on January 2, 2026. This is routine insider liquidity event with no disclosed material adverse information.

Rocket Lab officer Adam C. Spice filed Form 144 on March 2, 2026, notifying the proposed sale of 62,744 common shares valued at $4.37 million. The sale covers tax obligations from the vesting of 114,845 restricted stock units on March 1, 2026. This is routine insider activity following a larger sale by Spice in January.

Rocket Lab reported record annual revenue of $602M for 2025, representing 38% year-on-year growth, alongside a record $1.85B backlog. The company successfully completed 21 launches and secured an $816M SDA contract, though it reported a net loss of $198.2M for the year.

FY25 revenue reached $602M, up 38% YoY, driven by 59% growth in Launch Services from higher cadence and 30% in Space Systems. Gross margins expanded to 34% from 27% YoY on production efficiencies. Operating loss narrowed to -38% amid Neutron investments.